Clinical Trials Browser

Active not recruiting × Leukemia × Vemurafenib × Clear all

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell